Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app keep heart patients out of the hospital? new study aims to find out.

NCT ID NCT07557147

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated May 16, 2026 · Updated 1 time

Summary

This study looks at whether a digital tool called Luscii is practical and acceptable for people with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare heart condition. About 60 adults in Austria, Germany, and Italy will use the app at home to share health information with their care team. No treatments are given; the goal is to see if remote monitoring can improve communication and catch problems earlier.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medizinische Universität Innsbruck

    Innsbruck, 6020, Austria

  • Policlinico San Matteo di Pavia

    Pavia, 27100, Italy

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120, Germany

Conditions

Explore the condition pages connected to this study.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)